MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma | Dr Georgina Long at ECC 2015

MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma | Dr Georgina Long at ECC 2015

EMJ

4 years
597 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety data from the phase 1b part of MASTERKEY-265 , a phase 1b/3 clinical trial that was designed to evaluate the treatment of talimogene laherparepvec (T-VEC), a herpes simplex virus-1, and pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with unresectable stage IIIB-IV melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay